![]() ![]() Recently it was shown that hyperthermic intraperitoneal chemotherapy (HIPEC) given at the time of surgery resulted in longer recurrence free survival and overall survival when compared to surgery alone. This study showed that IP delivery of agents was a viable therapeutic option, and that IP therapy could increase efficacy of treatment. The IP regimen resulted in a 15-month increase in overall survival compared to the standard IV therapy. Patients with stage III optimally resected cancer were given cisplatin intraperitoneal (IP) and paclitaxel intravenous (IV) and IP, compared to standard IV administration of both drugs. In 2006 there was a major advance in the treatment of some women diagnosed with EOC. The presence of the bulk of disease in the peritoneal cavity, and the semi-permeable nature of the peritoneum, makes ovarian cancer an ideal candidate for the use of locoregional therapy. In most women, mortality is associated with abdominal disease. Distant metastases (lung, brain) are infrequently found, and typically occur late in the course of disease. ĭespite the aggressive nature of ovarian cancer, and its high mortality rate, the disease is largely retained to the peritoneal cavity, with metastatic seeding to all of the major organs of the peritoneal cavity. Without curative second line treatment for patients with resistant or refractory epithelial ovarian cancer (EOC), median survival is 16 months, with most of the population dying within the first 2 years. ![]() The disease course is characterized by a high rate of relapse despite an initial good response to the therapy. Standard of care for the treatment of ovarian cancer is tumor cytoreductive surgery followed by administration of platinum and taxane based chemotherapy. Ovarian cancer is the leading cause of death due to gynecological malignancies, and the fifth leading cause of death due to cancer in women. ![]()
0 Comments
Leave a Reply. |